Floatz logo

Cixutumumab

Alveolar Soft Part Sarcoma

Explore 16 assets in Alveolar Soft Part Sarcoma →
Floatz Rating
B57/100
Confidence
Indicative
v0.2
Sponsor
National Cancer Institute (NCI)
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT01614795CT.gov
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Alveolar Soft Part Sarcoma

AssetSponsorPhaseRating
Cixutumumab (this asset)National Cancer Institute (NCI)P2B · 57
TivantinibArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)P2B
CrizotinibEuropean Organisation for Research and Treatment of Cancer - EORTCP2B
TemsirolimusNational Cancer Institute (NCI)P2B
CabozantinibNational Cancer Institute (NCI)P2CCC
VismodegibNational Cancer Institute (NCI)P1/2CCC
ZoledronateUniversity of FloridaP1/2CC
GVAXDana-Farber Cancer InstituteP1CC
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Tigit (T-Cell Immunoreceptor With Ig Domain And Itim, V-Set Ig Member 9, Vsig9, V-Set And Transmembrane Member 3, Vstm3)], Humanized Monoclonal Antibody; Gamma1 Heavy Chain Humanized (1-448) [Vh (Homo Sapiens Ighv3-48*01 (90.8%) -(Ighd) -Ighj4*01 (92.3%)) Cdr-Imgt [8.8.12] (26-33.51-58.97-108) (1-119) -Homo Sapiens Ighg1*01, G1M17,1, G1V14 Ch2 A1.3, A1.2 (Ch1 K120 (216) (120-217), Hinge 1-15 (218-232), Ch2 L1.3>A (236), L1.2>A (237) (233-342), Ch3 D12 (358), L14 (360) (343-447), Chs K>Del (448)) (120-448)], (222-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-16*01 (89.5%) -Igkj4*01 (100%)) Cdr-Imgt [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo Sapiens Igkc*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In A Chinese Hamster Ovary (Cho)-K1 Cell Line, Glycoform AlfaTaiho Pharmaceutical Co., Ltd.P1CC

+14 more in the Alveolar Soft Part Sarcoma cohort

Other indications for Cixutumumab

IndicationSponsorPhaseRating
Non-Small Cell Lung Carcinoma—P2BB · 71
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor—P2BB · 69
Prostate Carcinoma—P2BB · 67

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Cixutumumab in Alveolar Soft Part Sarcoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/cixutumumab-alveolar-soft-part-sarcoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →